Sorry, your browser does not support JavaScript!
Medicine Questions
Report an Adverse Event
Investors
Contact
Global Operations
North America
Canada
Mexico
USA
South America
Argentina
Brazil
Asia
China Mainland
Hong Kong
India
Japan
Korea
Singapore
Taiwan
Middle East
Israel
Saudi Arabia
Türkiye
United Arab Emirates
Africa
South Africa
Australia
Australia and New Zealand
Europe
Austria
Belgium and Luxembourg
Czech Republic & Slovakia
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Romania
Russia
Spain
Sweden
Switzerland
United Kingdom
Our Company
Mission and Core Values
Leadership
U.S. Public Policy Engagement
Policies and Disclosures
Supplier Information
U.S. Locations
Our Purpose
Partnerships and Community
Corporate Giving
Gilead Foundation
Inclusion and Diversity
Environmental, Social, Governance (ESG)
Sustainability
Advancing Global Health
Medication Access
Science & Medicine
Therapeutic Areas
Medicines
Pipeline
Research
Clinical Trials
News and Press
Events
Stories
Newsroom
Company Statements
Annual Reports
Careers
Careers at Gilead
Our Culture
Meet Our Employees
Inclusion and Diversity in Hiring
Compensation, Benefits and Wellbeing
Our Global Footprint
Early Career Opportunities
Postdoctoral Fellowships
Hiring Events
Talent Community Sign-up
Utility
Privacy Statements
Terms Of Use
Social Media Guidelines
Sitemap
BACK TO MAIN MENU
Leadership
Governance and Committees
BACK TO MAIN MENU
U.S. Public Policy Engagement
Political Contributions Archives
BACK TO MAIN MENU
Policies and Disclosures
Policies
Disclosures
BACK TO MAIN MENU
Supplier Information
Supplier Enablement Resources
Supplier Inclusion
BACK TO MAIN MENU
Partnerships and Community
COMPASS Initiative
HepConnect
HIV Age Positively
Toward Health Equity for Black People Impacted by TNBC
RADIAN
TRANScend
BACK TO MAIN MENU
Corporate Giving
What We Fund
Funding Requests
Zeroing In: Ending the HIV Epidemic
BACK TO MAIN MENU
Gilead Foundation
Creating Possible Fund
BACK TO MAIN MENU
Environmental, Social, Governance (ESG)
Reporting
U.N. Global Compact
U.N. Sustainable Development Goals
BACK TO MAIN MENU
Sustainability
Our Business Is Sustainable
Performance
BACK TO MAIN MENU
Advancing Global Health
COVID-19
HCV Elimination
BACK TO MAIN MENU
Medication Access
U.S. Patient Access
Disaster Product Replacement
Global Access
Authorized Distributors
BACK TO MAIN MENU
Research
Research Scholars Program
Compassionate Use
Investigator-Sponsored Research
BACK TO MAIN MENU
Newsroom
Press Releases
Media Inquiries
BACK TO MAIN MENU
Company Statements
Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries
Christi Shaw to Depart Gilead and Kite Leadership End of Q1
Gilead Sciences Commends Convictions in Counterfeiting Scheme Pledges Continued Commitment to Protect Patients
Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S.
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products
Gilead to Expand Footprint in Oceanside
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD
Gilead Sciences Statement on Recent Events in Washington, D.C.
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
BACK TO MAIN MENU
Annual Reports
Year in Review 2021
BACK TO MAIN MENU
Early Career Opportunities
Internship Program
BACK TO MAIN MENU
Privacy Statements
Cookie Statement
Global Applicant Privacy Statement
BACK TO MAIN MENU
North America
Canada
Mexico
USA
South America
Argentina
Brazil
Asia
China Mainland
Hong Kong
India
Japan
Korea
Singapore
Taiwan
Middle East
Israel
Saudi Arabia
Türkiye
United Arab Emirates
Africa
South Africa
Australia
Australia and New Zealand
Europe
Austria
Belgium and Luxembourg
Czech Republic & Slovakia
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Romania
Russia
Spain
Sweden
Switzerland
United Kingdom
BACK TO MAIN MENU
Contact
Request Medicines Information
Report an Adverse Event
Partnership Request
Search Term
Medicine Questions
Report an Adverse Event
Investors
Contact
Global Operations
Toggle Inner Dropdown
BACK TO MAIN MENU
Google.com
Headline
Close
×
Intersititial body copy
